Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-24-058318
Filing Date
2024-05-08
Accepted
2024-05-07 21:52:05
Documents
5
Period of Report
2024-06-21

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm242764-1_def14a.htm DEF 14A 747055
2 GRAPHIC bc_paidvsnetloss-4c.jpg GRAPHIC 63859
3 GRAPHIC bc_paidvstsr-4c.jpg GRAPHIC 51873
4 GRAPHIC px_24cyclacelpxy1pg01-bw.jpg GRAPHIC 244178
5 GRAPHIC px_24cyclacelpxy1pg02-bw.jpg GRAPHIC 223906
  Complete submission text file 0001104659-24-058318.txt   1487693
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-50626 | Film No.: 24924023
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)